Novavax Shares Surge on Surprise Swing to 4Q Profit

Dow Jones

Yesterday

By Amira McKee

Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals.

The stock leapt 16% to $11.03 in Thursday afternoon trading, marking a new 52-week high. The shares have gained 50% in the past year.

The biotechnology company recorded fourth-quarter net income of $17.5 million, or 11 cents a share, compared with a net loss of $81 million, or 51 cents a share, a year earlier.

The results outperformed Wall Street's forecast for a loss of 48 cents a share, according to FactSet.

Revenue jumped 67% to $147.1 million, beating the $89.8 million that analysts polled by FactSet had expected.

Novavax halved its selling, general and administrative expenses in the quarter and cut its research-and-development spend by 24%. The company said it has exceeded its cost-cutting goals for 2025 with full-year R&D and SG&A expenses of $499.8 million. In 2026, the company plans to cut those costs further to $380 million to $420 million.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 26, 2026 12:57 ET (17:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2614022420"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614022420\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614022420?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614022420","market":"nz","top_or_hot":-1,"title":"Novavax Shares Surge on Surprise Swing to 4Q Profit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals. \n</p>\n<p>\n  The stock leapt 16% to $11.03 in Thursday afternoon trading, marking a new 52-week high. The shares have gained 50% in the past year. \n</p>\n<p>\n  The biotechnology company recorded fourth-quarter net income of $17.5 million, or 11 cents a share, compared with a net loss of $81 million, or 51 cents a share, a year earlier. \n</p>\n<p>\n  The results outperformed Wall Street's forecast for a loss of 48 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue jumped 67% to $147.1 million, beating the $89.8 million that analysts polled by FactSet had expected. \n</p>\n<p>\n  Novavax halved its selling, general and administrative expenses in the quarter and cut its research-and-development spend by 24%. The company said it has exceeded its cost-cutting goals for 2025 with full-year R&amp;D and SG&amp;A expenses of $499.8 million. In 2026, the company plans to cut those costs further to $380 million to $420 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2026 12:57 ET (17:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax Shares Surge on Surprise Swing to 4Q Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax Shares Surge on Surprise Swing to 4Q Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-27 01:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals. \n</p>\n<p>\n  The stock leapt 16% to $11.03 in Thursday afternoon trading, marking a new 52-week high. The shares have gained 50% in the past year. \n</p>\n<p>\n  The biotechnology company recorded fourth-quarter net income of $17.5 million, or 11 cents a share, compared with a net loss of $81 million, or 51 cents a share, a year earlier. \n</p>\n<p>\n  The results outperformed Wall Street's forecast for a loss of 48 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue jumped 67% to $147.1 million, beating the $89.8 million that analysts polled by FactSet had expected. \n</p>\n<p>\n  Novavax halved its selling, general and administrative expenses in the quarter and cut its research-and-development spend by 24%. The company said it has exceeded its cost-cutting goals for 2025 with full-year R&amp;D and SG&amp;A expenses of $499.8 million. In 2026, the company plans to cut those costs further to $380 million to $420 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 26, 2026 12:57 ET (17:57 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2614022420","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614022420","pubTimestamp":1772128620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals.The stock leapt 16% to $11.03 in Thursday afternoon trading, marking a new 52-week high. The shares have gained 50% in the past year.The biotechnology company recorded fourth-quarter net income of $17.5 million, or 11 cents a share, compared with a net loss of $81 million, or 51 cents a share, a year earlier.The results outperformed Wall Street's forecast for a loss of 48 cents a share, according to FactSet.Revenue jumped 67% to $147.1 million, beating the $89.8 million that analysts polled by FactSet had expected.Novavax halved its selling, general and administrative expenses in the quarter and cut its research-and-development spend by 24%. The company said it has exceeded its cost-cutting goals for 2025 with full-year R&D and SG&A expenses of $499.8 million. In 2026, the company plans to cut those costs further to $380 million to $420 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NVAX":"诺瓦瓦克斯医药","BK4585":"ETF&股票定投概念","BK4568":"美国抗疫概念","BK4588":"碎股","BK4547":"WSB热门概念"},"translate_title":"Novavax股价因第四季度利润意外波动而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1.5},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of Novavax soared after the company swung to an unexpected profit in the fourth quarter and exceeded its expense-reduction goals. \n\n\n  The stock leapt 16% to $11.03 in Thursday afternoon trading, marking a new 52-week high. The shares have gained 50% in the past year. \n\n\n  The biotechnology company recorded fourth-quarter net income of $17.5 million, or 11 cents a share, compared with a net loss of $81 million, or 51 cents a share, a year earlier. \n\n\n  The results outperformed Wall Street's forecast for a loss of 48 cents a share, according to FactSet. \n\n\n  Revenue jumped 67% to $147.1 million, beating the $89.8 million that analysts polled by FactSet had expected. \n\n\n  Novavax halved its selling, general and administrative expenses in the quarter and cut its research-and-development spend by 24%. The company said it has exceeded its cost-cutting goals for 2025 with full-year R&D and SG&A expenses of $499.8 million. In 2026, the company plans to cut those costs further to $380 million to $420 million. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 12:57 ET (17:57 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}